231,040 Shares in BridgeBio Oncology Therapeutics, Inc $BBOT Bought by Granahan Investment Management LLC

Granahan Investment Management LLC purchased a new position in shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) during the first quarter, Holdings Channel.com reports. The institutional investor purchased 231,040 shares of the company’s stock, valued at approximately $2,068,000.

A number of other hedge funds also recently made changes to their positions in the business. CIBC Private Wealth Group LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth about $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth about $144,000. Quadrature Capital Ltd bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth about $162,000. Finally, BIT Capital GmbH acquired a new stake in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $313,000. Institutional investors and hedge funds own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Trading Up 1.1%

Shares of BridgeBio Oncology Therapeutics stock opened at $8.82 on Friday. The firm has a 50 day moving average of $8.20. BridgeBio Oncology Therapeutics, Inc has a fifty-two week low of $7.00 and a fifty-two week high of $14.87. The firm has a market capitalization of $706.57 million, a price-to-earnings ratio of -4.30 and a beta of 0.39.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. Equities analysts anticipate that BridgeBio Oncology Therapeutics, Inc will post -2.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on BridgeBio Oncology Therapeutics in a report on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 target price for the company. UBS Group downgraded BridgeBio Oncology Therapeutics to an “overweight” rating in a research report on Wednesday, July 8th. Wall Street Zen raised BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th. Finally, Oppenheimer began coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, June 22nd. They issued an “outperform” rating and a $22.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.80.

BridgeBio Oncology Therapeutics Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.